Palmitoylation stabilizes PD-L1 to promote breast tumor growth.
作者信息
Yang Yi, Hsu Jung-Mao, Sun Linlin, Chan Li-Chuan, Li Chia-Wei, Hsu Jennifer L, Wei Yongkun, Xia Weiya, Hou Junwei, Qiu Yufan, Hung Mien-Chie
机构信息
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, 30052, China.
出版信息
Cell Res. 2019 Jan;29(1):83-86. doi: 10.1038/s41422-018-0124-5. Epub 2018 Dec 4.
Abstract
摘要
相似文献
1
Palmitoylation stabilizes PD-L1 to promote breast tumor growth.棕榈酰化使程序性死亡受体配体1（PD-L1）稳定，以促进乳腺肿瘤生长。
Cell Res. 2019 Jan;29(1):83-86. doi: 10.1038/s41422-018-0124-5. Epub 2018 Dec 4.
2
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.抑制 PD-L1 的棕榈酰化可增强 T 细胞对肿瘤的免疫反应。
Nat Biomed Eng. 2019 Apr;3(4):306-317. doi: 10.1038/s41551-019-0375-6. Epub 2019 Mar 25.
3
Biomarkers for assessing the effectiveness of immunotherapy in breast cancer.用于评估乳腺癌免疫治疗效果的生物标志物。
Biomark Med. 2018 Feb;12(2):97-100. doi: 10.2217/bmm-2017-0408. Epub 2018 Jan 17.
4
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.在直肠腺癌患者中，PD-L1 由放化疗上调，并与良好的预后相关。
Eur J Cancer. 2016 Sep;65:52-60. doi: 10.1016/j.ejca.2016.06.015. Epub 2016 Jul 25.
5
Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylation.ZDHHC9 在肺腺癌中的作用：通过棕榈酰化调节 PD-L1 的稳定性。
In Vitro Cell Dev Biol Anim. 2023 Mar;59(3):193-203. doi: 10.1007/s11626-023-00755-5. Epub 2023 Mar 31.
6
PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.PD-1、PD-L1 和 CTLA-4 在妊娠相关和早发性乳腺癌中的表达：一项比较研究。
Breast. 2017 Oct;35:69-77. doi: 10.1016/j.breast.2017.06.013. Epub 2017 Jun 23.
7
Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.程序性细胞死亡配体 1 在伴有间质性肺疾病的非小细胞肺癌患者中的表达：一项匹配病例对照研究。
Clin Lung Cancer. 2018 Sep;19(5):e667-e673. doi: 10.1016/j.cllc.2018.04.012. Epub 2018 May 5.
8
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.组蛋白乙酰转移酶 1 过表达通过增加胰腺癌中程序性死亡配体 1 的表达来调节癌症免疫。
J Exp Clin Cancer Res. 2019 Feb 1;38(1):47. doi: 10.1186/s13046-019-1044-z.
9
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.使用抗程序性死亡配体1（PD-L1）抗体阿维鲁单抗进行近红外光免疫治疗。
Oncotarget. 2017 Jan 31;8(5):8807-8817. doi: 10.18632/oncotarget.12410.
10
Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.程序性细胞死亡配体-1在肺腺癌中的表达的临床病理及预后意义及其与p53状态的关系
Lung Cancer. 2016 Jul;97:73-80. doi: 10.1016/j.lungcan.2016.05.001. Epub 2016 May 3.
引用本文的文献
1
Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation to Suppress YAP-Driven Cancer Metastasis.靶向DHHC9介导的STRN4棕榈酰化以抑制YAP驱动的癌症转移的药理学研究
J Cell Mol Med. 2025 Sep;29(17):e70815. doi: 10.1111/jcmm.70815.
2
Recent advances in S-palmitoylation and its emerging roles in human diseases.S-棕榈酰化的最新进展及其在人类疾病中的新作用。
J Hematol Oncol. 2025 Sep 1;18(1):83. doi: 10.1186/s13045-025-01738-7.
3
Palmitoylation: an emerging therapeutic target bridging physiology and disease.棕榈酰化：连接生理与疾病的新兴治疗靶点。
Cell Mol Biol Lett. 2025 Aug 15;30(1):98. doi: 10.1186/s11658-025-00776-w.
4
Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges.癌症中的棕榈酸与棕榈酰化：认识、见解与挑战
Innovation (Camb). 2025 Apr 29;6(8):100918. doi: 10.1016/j.xinn.2025.100918. eCollection 2025 Aug 4.
5
Multi-omics-based construction of a palmitoylation-driven prognostic model reveals tumor immune phenotypes in osteosarcoma.基于多组学构建棕榈酰化驱动的预后模型揭示骨肉瘤的肿瘤免疫表型
Discov Oncol. 2025 Aug 13;16(1):1544. doi: 10.1007/s12672-025-03364-8.
6
A lipid metabolism-related gene signature predicts prognosis after tamoxifen treatment in ER + breast cancer and reflects tumor microenvironment heterogeneity through single-cell analysis.一种脂质代谢相关基因特征可预测雌激素受体阳性乳腺癌患者接受他莫昔芬治疗后的预后，并通过单细胞分析反映肿瘤微环境的异质性。
BMC Med Genomics. 2025 Jul 31;18(1):123. doi: 10.1186/s12920-025-02194-5.
7
Systematic analysis of ZDHHC9 as a potential prognostic and immunotherapy biomarker in breast cancer.ZDHHC9作为乳腺癌潜在预后和免疫治疗生物标志物的系统分析。
Front Immunol. 2025 Jul 16;16:1609621. doi: 10.3389/fimmu.2025.1609621. eCollection 2025.
8
Role of S-palmitoylation in digestive system diseases.S-棕榈酰化在消化系统疾病中的作用。
Cell Death Discov. 2025 Jul 18;11(1):331. doi: 10.1038/s41420-025-02629-z.
9
S-palmitoylation: a novel insight in the development and immunotherapy of oral squamous cell carcinoma.S-棕榈酰化：口腔鳞状细胞癌发生发展及免疫治疗的新见解
J Cancer. 2025 Jun 12;16(9):2787-2799. doi: 10.7150/jca.110721. eCollection 2025.
10
Research trends of protein palmitoylation in cancer from 2004 to 2024: a bibliometric and visualization analysis.2004年至2024年癌症中蛋白质棕榈酰化的研究趋势：文献计量与可视化分析
Front Oncol. 2025 Jun 23;15:1571870. doi: 10.3389/fonc.2025.1571870. eCollection 2025.
本文引用的文献
1
Emerging Roles of DHHC-mediated Protein S-palmitoylation in Physiological and Pathophysiological Context.DHHC 介导的蛋白 S-棕榈酰化在生理和病理生理背景下的新兴作用。
Eur J Cell Biol. 2018 Jun;97(5):319-338. doi: 10.1016/j.ejcb.2018.03.005. Epub 2018 Mar 22.
2
Regulation and Function of the PD-L1 Checkpoint.PD-L1 检查点的调控与功能
Immunity. 2018 Mar 20;48(3):434-452. doi: 10.1016/j.immuni.2018.03.014.
3
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.周期蛋白 D-CDK4 激酶通过 Cullin3-SPOP 使 PD-L1 不稳定，从而控制癌症免疫监视。
Nature. 2018 Jan 4;553(7686):91-95. doi: 10.1038/nature25015. Epub 2017 Nov 16.
4
EZH2 Palmitoylation Mediated by ZDHHC5 in p53-Mutant Glioma Drives Malignant Development and Progression.ZDHHC5 介导的 EZH2 棕榈酰化在 p53 突变型胶质瘤中驱动恶性发展和进展。
Cancer Res. 2017 Sep 15;77(18):4998-5010. doi: 10.1158/0008-5472.CAN-17-1139. Epub 2017 Aug 3.
5
Palmitoylation: a protein -acylation with implications for breast cancer.棕榈酰化：一种与乳腺癌相关的蛋白质酰化作用
NPJ Breast Cancer. 2016 Oct 19;2:16028. doi: 10.1038/npjbcancer.2016.28. eCollection 2016.
6
Palmitoylation of proteins in cancer.癌症中蛋白质的棕榈酰化作用
Biochem Soc Trans. 2017 Apr 15;45(2):409-416. doi: 10.1042/BST20160233.
7
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.糖基化和程序性死亡配体 1 的稳定抑制 T 细胞活性。
Nat Commun. 2016 Aug 30;7:12632. doi: 10.1038/ncomms12632.
8
Palmitoylation regulates the intracellular trafficking and stability of c-Met.棕榈酰化调节c-Met的细胞内运输和稳定性。
Oncotarget. 2016 May 31;7(22):32664-77. doi: 10.18632/oncotarget.8706.
9
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.用于癌症治疗的PD-L1（B7-H1）和PD-1通路阻断：作用机制、反应生物标志物及联合应用
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
10
Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.TEAD转录因子的棕榈酰化对于其在河马信号通路中的稳定性和功能是必需的。
Structure. 2016 Jan 5;24(1):179-186. doi: 10.1016/j.str.2015.11.005. Epub 2015 Dec 24.
Zotero 插件